Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 01, 2022

SELL
$0.2 - $0.5 $6,132 - $15,330
-30,661 Closed
0 $0
Q1 2022

May 10, 2022

SELL
$0.41 - $0.63 $2,076 - $3,190
-5,064 Reduced 14.17%
30,661 $17,000
Q4 2021

Feb 08, 2022

BUY
$0.57 - $1.29 $8,417 - $19,050
14,768 Added 70.47%
35,725 $20,000
Q3 2021

Nov 12, 2021

SELL
$1.11 - $1.7 $23,830 - $36,497
-21,469 Reduced 50.6%
20,957 $26,000
Q2 2021

Aug 13, 2021

BUY
$1.46 - $2.25 $61,941 - $95,458
42,426 New
42,426 $72,000
Q4 2017

Feb 14, 2018

SELL
$1.4 - $2.6 $52,466 - $97,437
-37,476 Closed
0 $0
Q3 2017

Nov 13, 2017

BUY
$2.22 - $2.79 $6,016 - $7,560
2,710 Added 7.79%
37,476 $96,000
Q2 2017

Aug 11, 2017

BUY
N/A
34,766
34,766 $80,000

About TREVENA INC


  • Ticker TRVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 173,680,992
  • Market Cap $273M
  • Description
  • Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...
More about TRVN
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.